Tag: Neuro-spinal scaffold
InVivo halts enrolment in cervical study of neuro-spinal scaffold, lays off...
InVivo Therapeutics is to cease enrolment in its recently-announced cervical study of the company’s Neuro-spinal scaffold. The company has also halted its chronic spinal...
Two new patients convert in Invivo Therapeutics’ INSPIRE trial
Invivo Therapeutics has provided an update on the progress of the company’s INSPIRE study (Invivo Study of Probable Benefit of the Neuro-Spinal Scaffold for...
First UK centre joins Invivo Therapeutics’ INSPIRE study
James Cook University Hospital in Middlesbrough, UK, has been added as the country’s first clinical site for Invivo Therapeutics’ INSPIRE study (InVivo Study of...
UCHealth Memorial Hospital new site for InVivo Therapeutics’ INSPIRE study
InVivo Therapeutics hasannounced that the UCHealth Memorial Hospital in Colorado Springs, USA has been added as a clinical site for the INSPIRE study (InVivo...
Two InVivo Therapeutics INSPIRE patients convert AIS grade
InVivo Therapeutics has announced that two patients in the INSPIRE study of the Neuro-Spinal Scaffold have improved from sensory incomplete AIS B spinal cord...
New patient enrolled in InVivo Therapeutics’ INSPIRE study
InVivo Therapeutics has announced that a new patient has been enrolled into the INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold...
New patient enrolled in InVivo Therapeutics INSPIRE study
A new patient has been enrolled into InVivo Therapeutics' INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic...
InVivo to include international registry data in sister study to INSPIRE
InVivo Therapeutics has announced that data from the Christopher & Dana Reeve Foundation NACTN Registry will be included in the Contemporary Thoracic SCI registry...
New patient enrolled in InVivo INSPIRE study
A new patient has been enrolled into InVivo Therapeutics’ INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic...
InVivo Therapeutics announces first Canadian site for cervical spinal cord injury...
InVivo Therapeutics has received approval from the Toronto Western Hospital’s Research Ethics Board to enrol patients as part of its cervical spinal cord injury...
Seventh InVivo Therapeutics INSPIRE patient converts AIS grade
InVivo Therapeutics has announced that the patient enrolled in January in the INSPIRE study of the Neuro-spinal scaffold has improved from a complete AIS...
InVivo Therapeutics announces new cervical spinal cord injury study
Health Canada has approved Invivo Therapeutics’ Investigational Testing Authorization application to commence a clinical study of the Neuro-spinal scaffold in patients with acute, complete...
InVivo Therapeutics enrols Keck Hospital patient into INSPIRE study
A new patient has been enrolled into InVivo Therapeutics’ INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold for Safety and Neurologic...
Securities and Exchange Commission temporarily suspends trade of PixarBio stock
PixarBio stock has been suspended from trade by the Securities and Exchange Commission, in line with the Securities Exchange Act of 1934. The Commission...
Sixth INSPIRE patient improves ASIA score
An Invivo Therapeutics INSPIRE study patient enrolled in December 2016 has improved from a complete ASIA A spinal cord injury to an incomplete ASIA...
New patient enrolled into Invivo Therapeutics INSPIRE study
A new patient has been enrolled into Invivo Therapeutics’ INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-spinal scaffold for Safety and Neurologic...
New Mexico Hospital joins Invivo’s INSPIRE study
The University of New Mexico Hospital (UNMH) in Albuquerque, USA, has been added as a clinical site for the INSPIRE (Invivo Study of Probable...
St Michael’s Hospital, Toronto, Canada, joins InVivo Therapeutics’ INSPIRE study
The St Michael’s Hospital in Toronto has been added as a Canadian clinical site for Invivo Therapeutics’ INSPIRE study (InVivo Study of Probable Benefit...
InVivo Therapeutics clashes with PixarBio over proposed takeover
Invivo Therapeutics has rebuked a press release from PixarBio claiming that it had made a US$77,000,000 stock offer to acquire the company.
The colourfully-worded release,...
Tenth patient enrolled in InVivo Therapeutics’ INSPIRE study
A new patient with a T8-9 fracture dislocation injury has been enrolled into InVivo Therapeutics’ INSPIRE Study (InVivo Study of Probable Benefit of the...
Melanie Morel-Ferris replaces Steven McAllister as interim chief financial officer at...
InVivo Therapeutics has announced the resignation of Steven McAllister from the position of chief financial officer effective December 31, 2016. According to a company...
New participant enrolled in Invivo Therapeutics’ INSPIRE study
InVivo Therapeutics has announced that a new patient has been enrolled into the INSPIRE study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold...
Beth Israel Deaconess Medical Center joins Invivo Therapeutics’ INSPIRE study
Beth Israel Deaconess Medical Center in Boston, USA has been added as a clinical site for the INSPIRE study (InVivo Study of Probable Benefit...
Calgary centre added as new Canadian InVivo Therapeutics INSPIRE study site
The Foothills Medical Centre in Calgary has been added as a Canadian clinical site for InVivo Therapeutics’ INSPIRE study (InVivo Study of Probable Benefit...
Fifth INSPIRE study patient improves, Northwestern Medicine added as clinical site
The ninth spinal cord injury patient in the INSPIRE trial—implanted with InVivo Therapeutics’ neuro-spinal scaffold last month—is showing signs of improvement. The patient is...
Pamela Stahl appointed chief commercial officer of InVivo Therapeutics
InVivo Therapeutics Holdings has appointed Pamela Stahl to the newly-created position of chief commercial officer, effective September 14, 2016.
Prior to joining InVivo, Stahl served...